## Leprosy Classification and Treatment: Smear-Based WHO Classification **Key Point:** According to WHO guidelines, a **slit-skin smear of 2+ or higher at any site classifies the patient as Multibacillary (MB) leprosy**, regardless of the clinical morphological type. This patient's 2+ smear mandates the **MB regimen: Rifampicin + Dapsone + Clofazimine for 12 months**. ### Classification Rationale | Feature | Paucibacillary (PB) | Multibacillary (MB) | |---|---|---| | Slit-skin smear | Negative (0) | **1+ or higher at any site** | | Skin lesions | 1–5 | 6 or more (clinical guide) | | Clinical types | TT, BT | BB, BL, LL | | Regimen | 2 drugs, 6 months | **3 drugs, 12 months** | **Critical Rule:** The slit-skin smear result **overrides** the clinical morphological classification for treatment purposes. Even though borderline tuberculoid (BT) leprosy is classically described as paucibacillary, a positive smear of **2+** places this patient firmly in the **MB category** requiring triple therapy. ### WHO Multibacillary (MB) Regimen 1. **Rifampicin 600 mg** once monthly (supervised) 2. **Dapsone 100 mg** daily (self-administered) 3. **Clofazimine 300 mg** once monthly (supervised) + **50 mg** daily (self-administered) 4. **Duration:** 12 months ### Why Each Drug? | Drug | Role | Mechanism | |---|---|---| | Rifampicin | Bactericidal (backbone) | Inhibits bacterial RNA polymerase; rapidly kills actively dividing bacilli | | Dapsone | Bacteriostatic | Inhibits dihydropteroate synthase; blocks folate synthesis | | Clofazimine | Bactericidal + anti-inflammatory | Binds mycobacterial DNA; also reduces ENL reactions | **Why not Option A (Rifampicin + Dapsone for 6 months)?** This is the PB regimen, applicable only when the smear is negative. Using it for a 2+ smear risks under-treatment, relapse, and drug resistance. **Why not Option B (Ofloxacin + Minocycline for 12 months)?** This combination is reserved for patients who cannot tolerate standard MDT drugs (e.g., rifampicin-intolerant or dapsone-intolerant patients) — not first-line therapy. **Why not Option C (Rifampicin monotherapy for 6 months)?** Monotherapy is never recommended in leprosy due to the high risk of resistance development. **High-Yield:** The smear result is the **gold standard** for WHO classification. A 2+ smear = MB = triple therapy for 12 months, regardless of clinical type. **Clinical Pearl:** Borderline tuberculoid leprosy is immunologically unstable. A positive smear (2+) indicates a higher bacillary load than typical BT, reinforcing the need for the more intensive MB regimen to prevent relapse and reversal reactions. **Mnemonic:** **MB = More Bacilli = More drugs (3) = More months (12)** [cite: Park's Textbook of Preventive and Social Medicine, 26th ed., Ch. 8; WHO Leprosy Guidelines 2018; Jopling & McDougall — Handbook of Leprosy]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.